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Abstract
Many Canadian cities are experiencing ongoing infectious disease and overdose epidemics among
injection drug users (IDUs). In particular, Human Immunodeficiency Virus (HIV) and hepatitis C
Virus (HCV) have become endemic in many settings and bacterial and viral infections, such as
endocarditis and cellulitis, have become extremely common among this population. In an effort to
reduce these public health concerns and the public order problems associated with public injection
drug use, in September 2003, Vancouver, Canada opened a pilot medically supervised safer injecting
facility (SIF), where IDUs can inject pre-obtained illicit drugs under the supervision of medical staff.
The SIF was granted a legal exemption to operate on the condition that its impacts be rigorously
evaluated. In order to ensure that the evaluation is appropriately open to scrutiny among the public
health community, the present article was prepared to outline the methodology for evaluating the
SIF and report on some preliminary observations. The evaluation is primarily structured around a
prospective cohort of SIF users, that will examine risk behavior, blood-borne infection
transmission, overdose, and health service use. These analyses will be augmented with process data
from within the SIF, as well as survey's of local residents and qualitative interviews with users, staff,
and key stakeholders, and standardised evaluations of public order changes. Preliminary
observations suggest that the site has been successful in attracting IDUs into its programs and in
turn helped to reduce public drug use. However, each of the indicators described above is the
subject of a rigorous scientific evaluation that is attempting to quantify the overall impacts of the
site and identify both benefits and potentially harmful consequences and it will take several years
before the SIF's impacts can be appropriately examined.
Introduction
Many Canadian cities are currently experiencing Human
Immunodeficiency Virus (HIV) and hepatitis C virus
(HCV) epidemics as a result of illicit injection drug use
[1,2]. Other costly infectious diseases that can be easily
acquired from non-hygenic injection practices, such as
endocarditis and cellulitis, are also common [3]. The
health of injection drug users (IDUs) is further compro-
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mised by avoidance and erratic use of primary care serv-
ices, costly emergency room visits, and acute care
hospitalizations [3-6]. Public drug use also occurs in
many inner city neighborhoods, and public drug use and
the unsafe disposal of syringes is a major community con-
cern [7,8].
In over two dozen European cities and more recently in
Sydney, Australia, safer injection facilities (SIFs), where
injection drug users can inject pre-obtained illicit drugs,
have been implemented in an effort to reduce the com-
munity and public health impacts of illicit drug use [9].
SIF typically have several primary objectives including: the
reduction of public drug use, fatal and non-fatal overdose,
and infectious disease risk; improving contact between a
highly marginalized 'at-risk' population and the health-
care system; and enhancing recruitment into medical care
and addiction treatment [9-11]. Within SIFs, IDUs are
provided with clean injecting equipment, medical atten-
tion in the event of overdose, as well as access to or referral
to primary healthcare and other services including addic-
tion treatment.
While it must be stressed that limited quantitative data are
presently available, various reports have credited SIFs with
a number of public health and community benefits
including: improving the health and social functioning of
their clients [11], while reducing overdose deaths [12],
risk behaviors known to transmit infectious diseases [13],
improperly discarded syringes [14], and public drug use
[15]. In addition, improved access to medical care and
drug treatment has been attributed to SIF attendance
[10,16]. A limitation of these earlier analyses is that, in a
number of settings, there has not been a commitment on
the part of health agencies to fund comprehensive evalua-
tions, and in many instances there have not existed pro-
spective cohorts to inform examinations of SIF's impacts
[17].
On September 22, 2003 Vancouver, Canada opened
North America's first government sanctioned SIF pilot
study [18]. Federal government approval for the three-
year pilot study was granted on the condition that the
health and social impacts of the SIF be the subject of a rig-
orous scientific evaluation. More recently, several Cana-
dian cities have begun to consider their own SIF
evaluations, including Montreal and Victoria [19,20].
Since several years were devoted to the development of
the Vancouver SIF evaluation methodology, and since the
investigators wished to be as open with methodology as
possible [21], the present article was prepared to describe
the framework of the evaluation and to report on prelim-
inary observations. The publication of these observations
may also be useful for other Canadian considering initiat-
ing SIF trials [19,20].
Client Anonymity
Prior to the opening of the SIF, a major concern with the
evaluation related to willingness of the target community
to use the injection facility [18]. In order to attract the tar-
get population without raising fears about confidentiality,
and to make the service as low threshold as possible, all
clients of the SIF can remain anonymous. Since fears
regarding reduced willingness to use SIF, if client registra-
tion was required, were observed in feasibility studies con-
ducted prior to Insite's opening [18], the SIF operated as a
completely low threshold service in the first 6 months of
operation and maximizing access to the SIF was the top
priority. During this time only paper records were main-
tained. After 6 months of operation, and after trust was
developed between the SIF operators and the target com-
munity, service use was tracked at an individual level
using a database that tracks all client service use and out-
comes within Insite. The phasing in of a digital tracking
system was successful, although service uptake was so sub-
stantial and immediate after the site opened, it is not
known if this was necessary. A further challenge was the
ethical dilemma posed by providing a health service that
must also be rigorously evaluated [22]. Specifically, it was
apparent to the investigators that it would be unethical to
limit use of the SIF to those who agreed to participate in
research. Instead, equipoise was reached by allowing par-
ticipation in surveys and other aspects of the research to
be optional to SIF users.
Aims of Insite
In brief, the aims of Insite are to reduce public injection
drug use and the unsafe disposal of syringes in public
spaces, the reduction of overdoses and infectious disease
risk, and improve access to healthcare services among
IDUs. The methodology for evaluating these aims is
described below and involves both a prospective cohort
design and additional data sources including evaluation
of community impacts.
Evaluation Methodology
Data Sources
The framework for the Vancouver SIF evaluation was
designed prior to the SIF's opening and involved a
number of methodological approaches. In light of the
lack of existing quantitative efficacy data [17], the exist-
ence of ethical concerns [22], and an awareness that a
non-randomized studies may be vulnerable to substantial
selection biases [23], the Vancouver SIF evaluation is pri-
marily structured around a prospective cohort design that
involves the longitudinal measurement of a number of
outcomes including blood-borne infection and overdose
incidence, risk behavior, drug use practices, such as public
drug use, and health services use.Harm Reduction Journal 2004, 1:9 http://www.harmreductionjournal.com/content/1/1/9
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The Vancouver SIF evaluation is somewhat unique
because of the availability of a number of pre-existing data
sources. These data sources include the community health
and safety evaluation (CHASE) cohort, which is a com-
munity recruited virtual cohort of Downtown Eastside res-
idents that prospectively and retrospectively examines
health service use in the community by linking to admin-
istrative health record databases. In addition, the Vancou-
ver Injection Drug Users Study (VIDUS) is an ongoing
prospective cohort study of injection drug users that
involves semi-annual serology of HIV and HCV as well as
a semi-annual questionnaire [24]. VIDUS and CHASE
allow for the description of IDUs in the community who
are using Insite and a comparison between those that are
and are not using the service.
In addition, in order to augment these data sources and to
allow for close examination of the characteristics of Insite
clients over time, a prospective cohort of Insite users has
also been established. The Scientific Evaluation of Super-
vised Injecting (SEOSI) cohort is based on a representative
sample of Insite users. The sample is derived through ran-
dom recruitment of Insite users who are offered an
informed consent to enroll into the study. Random
recruitment involves attending the SIF at times of the day
that are randomly selected using a random number gener-
ation program in SPSS, and inviting all users who use the
SIF at this time to enroll in the study. As with VIDUS, par-
ticipants provide a blood sample and conduct an inter-
viewer-administered questionnaire. The SEOSI
questionnaire deals with items that are particularly rele-
vant to Insite, such as risk behaviours, public drug use, sat-
isfaction with Insite, and access to medical care and
addiction treatment services. All SEOSI participants pro-
vide informed consent to link to the Insite database so
that SIF use can be tracked, as well as informed consent to
access administrative health record databases in the com-
munity. As of September 1, 2004 over 900 Insite users
have been enrolled into SEOSI and comparisons of socio-
demographic variables (age, gender, etc) has shown that
the SEOSI cohort is statistically similar to the overall
cohort of insight users (all p > 0.05).
Client Satisfaction
Measures of client satisfaction are compiled as part of the
SEOSI questionnaire. Through ratings of service quality in
terms of the 5 SERVQUAL dimensions: Tangibles (e.g., the
appearance of the physical facilities); Reliability (e.g., the
ability of staff to perform the service dependably);
Responsiveness (e.g., the willingness of staff to help cli-
ents and provide prompt service); Assurance (e.g., secu-
rity, credibility and courtesy); and Empathy (e.g., ease of
access, approachability and effort taken to understand cli-
ents' requirements). Similarly, reasons for avoiding the
service are measured among IDUs in VIDUS who have not
used Insite.
Additional Data Sources
These above prospective cohort data will be augmented by
a number of other data sources including: process indica-
tors, measures of community satisfaction and perceived
impact, standardized measures of public order, and qual-
itative and quantitative measures of the health of the tar-
get population. The collection of each of these data
sources is described below.
Process Measures
In order to track service use in the database at an individ-
ual level, while allowing for participant anonymity, each
client must select a unique client 'handle' or nickname.
The SIF database has a search function that allows for
rapid searches based on demographic information, such
as birth date, if an individual forgets their handle. Similar
anonymous tracking of individual clients is commonly
used at needle exchanges and other services for illicit
injection drug users [25].
A primary purpose of the evaluation is to measure process
indicators related to service uptake within the SIF, and this
is enabled through the Insite database. The database
tracks what drugs participants are consuming (heroin,
cocaine, etc) and what services, such as nursing care and
counseling services, are accessed by each client. For
instance, in the month of May 2004, over 1300 unique
visits were logged into the database.
Community and Staff Satisfaction
Community satisfaction and the perceived impact of the
SIF on business persons are measured through a commu-
nity survey that is performed in person among street
recruited residents and at street-level businesses. The sur-
vey is similar to surveys being used in the Sydney SIF trial,
and examines perceived changes in the neighborhood
after the SIF's opening. In addition, staff satisfaction with
the operation of the facility is measured through focus
groups and qualitative interviews with staff persons. These
interviews focus on how service delivery can be improved
and on what measures can be taken to ensure staff safety
and satisfaction.
Public Order
Standardized measures of public order were undertaken
to examine the impact of the SIF on several indicators of
public injection drug use. In brief, the survey protocol
involves measuring specified public order indicators
within an a priori defined geographical area in the neigh-
borhood and at a priori defined times of the week. Data
collection times are spread evenly throughout the week
and involved walking through the study zone in the sameHarm Reduction Journal 2004, 1:9 http://www.harmreductionjournal.com/content/1/1/9
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pattern. Measures of discarded syringes, injection-related
litter, and public injection drug use are all measured pro-
spectively. An evaluation of these indicators has recently
been described in detail [26].
Preliminary observations
Following the opening of the SIF in September 2003,
there was widespread support among the target popula-
tion with a steady increase in uptake during the first few
weeks. The site reached virtual capacity within two
months and currently an approximate average of 500
injections take place each day in the site. The busiest times
of the day are mid-afternoon and early evening at which
times demand often exceeds capacity and waiting times to
get into the 12 seat injection room can result in partici-
pants obtaining syringes and injecting elsewhere. Whether
the wait times are disproportionately affecting specific
populations is presently being investigated. Utilization
also fluctuates daily, peaking on the days leading up to,
and following welfare day. Exit surveys of IDU clients
have been widely supportive of the service and high levels
of satisfaction with the service among Insite staff have
been reported. Contrary to the suggestion that cocaine
users would be unwilling to use the SIF [9], approximately
half of all injections include cocaine.
Despite the chaotic behaviours often associated with
injection drug use, overall staff safety has been high and
the instances of verbal or physical abuse by clients are
managed efficiently as per the service's protocols. In out-
standing circumstances, Vancouver Police Department
has been called to remove disruptive clients, and support
and assistance from the police in this regard has been very
positive. Overall the staff remains very committed to the
activities at Insite and staff satisfaction has been high.
Overdoses, from a range of illicit drugs, are commonly
observed in the SIF. The severity of these overdoses range
from lowered respiration rate to severe emergency situa-
tions that have required the administration of naloxone
and ambulance responses. Given the high levels of illness
(for instance HIV and hepatitis C co-infection) and drug
using behaviours (unknown substances of unknown
purity) of the target population, it is not inconceivable
that a fatality could occur in the SIF despite staff supervi-
sion and emergency response.
There have been no instances where used syringe borrow-
ing has been seen within Insite. These behaviours are
common among street based injectors and it is well recog-
nized that these activities promote the spread of blood-
borne infections. It is also noteworthy that alcohol swabs
to clean the injection site, and clean water and cookers are
all provided to optimize hygenic injection procedures.
Research of street-based IDU in Vancouver has shown that
alcohol swabs are rarely used, and that non-hygenic water
sources, such as puddle water, are commonly used. It is
also noteworthy that within the SIF, safer hygenic injec-
tion practices are taught by the nursing staff to IDUs who
have never been shown how to inject safely.
In addition to supervising injections, teaching safer inject-
ing practices, and responding to overdoses, there has been
substantial health intervention within Insite. In particu-
lar, referrals to medical care at St Paul's Hospital are com-
mon as well as referrals to community health centres.
Early intervention for primary medical care concerns, such
as abscesses, is commonly provided by the Insite nursing
team, and coverage with public health interventions, such
as flu shots, has been provided to Insite users. In addition,
addictions counseling occurs on site and there have been
many referrals to detoxification programs and methadone
maintenance therapy.
Summary
Overall, Insite has attracted the target population and pre-
liminary evidence suggests that the experiences within
Insite as well as the community impact have been consist-
ent with the experience of over two dozen European set-
tings where SIF exist, and more recently Sydney, Australia.
The examination of early changes in public order has been
completed and there is strong evidence of improvement
in several indicators including public drug use [26].
However, each of the indicators described above is the
subject of a rigorous scientific evaluation that is attempt-
ing to quantify the overall impacts of the site and identify
both benefits and potentially harmful consequences over
a multi-year period. This evaluation is primarily struc-
tured around a prospective cohort design that will involve
the longitudinal measurement of health and community
indicators over the next several years. As such, it will be
some time before the overall impact of Insite on a number
of outcomes, such as blood-borne infections and IDUs
behavior, can be adequately quantified.
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